Population Council researchers will share new research and insights on the latest in the HIV and AIDS epidemic at the 10th IAS Conference on HIV Science (IAS 2019) in Mexico City, Mexico July 20-24. IAS 2019 is the largest open conference on HIV science in the world.
NEW YORK, NEW YORK (June 20, 2019) – The Lancet Global Health today published results from the Phase 3 clinical efficacy trials of the Population Council-developed Annovera™ (segesterone acetate and ethinyl estradiol vaginal contraceptive system). Annovera is the first and only contraceptive that provides an entire year of protection against unintended pregnancy while fully under a woman’s control. Results show that Annovera was 97% effective in preventing pregnancy for up to 13 menstrual cycles, which means that women do not need to return to the clinic or pharmacy for prescription refills.
Vancouver, Thursday, June 6, 2019 – A new study, conducted by the Population Council and with Women Deliver, found a strong and consistent lifelong negative association between giving birth before age 18 and a woman’s economic empowerment. The research, previewed today at the Women Deliver 2019 Conference, the world’s largest conference on gender equality and the health, rights, and wellbeing of girls and women, points to the critical need to strengthen sexual and reproductive health and rights and expand economic opportunities for girls and women throughout their lives.
The Population Council and partners are expanding the implementation of Biruh Tesfa, an evidence-based program conceptualized by the Population Council to reduce the social isolation of vulnerable girls in urban Ethiopia, to reach girls living in forced domestic servitude, girls who are trafficked, as well as girls living with disabilities in Ethiopia.
(November 28, 2018) NEW YORK, NY – The Population Council, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Los Angeles Biomedical Research Institute, and University of Washington School of Medicine today announced the launch of the first clinical trial to test the safety and efficacy of a gel for men to prevent unintended pregnancy. Three trial sites in the U.S. are now enrolling couples.
_211_141.jpg)
NEW YORK, NEW YORK (November 14, 2018) ̶ The Population Council has received initial funding from the Children’s Investment Fund Foundation (CIFF) to assess the feasibility of combining oral pre-exposure prophylaxis (PrEP) for HIV prevention with an oral contraceptive into a single pill, which women would take once a day.
October 24, 2018 -- Population Council researchers presented new evidence on promising biomedical and behavioral strategies to prevent HIV and other sexually transmitted infections at the HIV Research for Prevention (HIVR4P) conference in Madrid this week, the world’s only scientific meeting dedicated exclusively to biomedical HIV prevention.
New York, NY, 18 Oct. 2018 – Régine Sitruk-Ware, MD, distinguished scientist at the Population Council’s Center for Biomedical Research, has been named by TIME Magazine as one of the 50 Most Influential People in Health Care of 2018. Dr. Sitruk-Ware is being recognized for her research and leadership, which led to the recent U.S. FDA approval of Annovera™ (segesterone acetate and ethinyl estradiol vaginal system), the first and only contraceptive that provides an entire year of protection against unintended pregnancy while fully under a woman’s control.
_211_141.jpg)
September 24, 2018 – New research by the Population Council and partners shows that it may be possible to formulate a discreet, convenient, and woman-controlled multi-purpose technology to prevent HIV and other sexually transmitted infections (STIs) with limited risk of cross-resistance to antiretrovirals (ARV). This research published today in Nature Communications tests the non-antiretroviral agents, griffithsin (GRFT) and carrageenan (CG), in a fast-dissolving vaginal insert in rhesus macaques and mice.
The Population Council, a global nonprofit research organization, announced it has received U.S. Food and Drug Administration (FDA) approval for Annovera™ (segesterone acetate and ethinyl estradiol vaginal system), the first and only contraceptive that provides an entire year of protection against unintended pregnancy while fully under a woman’s control. The approval marks an important step toward expanding contraceptive options for women.
